Advanced search
Publication Cover
Future Oncology Volume 12, 2016 - Issue 17
Submit an article Journal homepage
741
Views
0
CrossRef citations to date
0
Altmetric
Conference Report

Inside the 2016 American Society of Clinical Oncology Genitourinary Cancers Symposium: Part 2 – Prostate and Bladder Cancer

Sebastiano Buti1 Medical Oncology Unit, University Hospital of Parma, Italy
,
Chiara Ciccarese2 Medical Oncology, Azienda Ospedaliera Universitaria Integrata, University of Verona, Verona, Italy
,
Roberto Iacovelli2 Medical Oncology, Azienda Ospedaliera Universitaria Integrata, University of Verona, Verona, Italy
,
Melissa Bersanelli1 Medical Oncology Unit, University Hospital of Parma, Italy
,
Marina Scarpelli3 Section of Pathological Anatomy, Polytechnic University of the Marche Region, School of Medicine, AOU Ospedali Riuniti, Ancona, Italy
,
Antonio Lopez-Beltran4 Department of Surgery, Cordoba University Medical School, Cordoba, Spain
,
Liang Cheng5 Department of Pathology & Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN, USA
,
Rodolfo Montironi3 Section of Pathological Anatomy, Polytechnic University of the Marche Region, School of Medicine, AOU Ospedali Riuniti, Ancona, Italy
,
Giampaolo Tortora2 Medical Oncology, Azienda Ospedaliera Universitaria Integrata, University of Verona, Verona, Italy
&
Francesco Massari6 Division of Oncology, S.Orsola-Malpighi Hospital, Bologna, ItalyCorrespondence[email protected]
 show all
Pages 1971-1974 | Received 05 Apr 2016, Accepted 19 May 2016, Published online: 17 Jun 2016

References

  • Lee WR , DignamJJ, AminMet al. NRG Oncology RTOG 0415: a randomized Phase III non-inferiority study comparing two fractionation schedules in patients with low-risk prostate cancer. J. Clin. Oncol.34(Suppl. 2S), Abstract 1 (2016).
  • Dearnaley DP , SyndikusI, MossopHet al. Comparison of hypofractionated high-dose intensity-modulated radiotherapy schedules for prostate cancer: RESULTS from the Phase III randomized CHHiP trial (CRUK/06/016). J. Clin. Oncol.34(Suppl. 2S), Abstract 2 (2016).
  • Shipley WU , PughSL, LukkaHRet al. NRG Oncology/RTOG 9601, a Phase III trial in prostate cancer patients: anti-androgen therapy (AAT) with bicalutamide during and after salvage radiation therapy (RT) following radical prostatectomy (RP) and elevated PSA. J. Clin. Oncol.34(Suppl. 2S), Abstract 3 (2016).
  • Bolla M , Van Den BerghACMet al. EORTC trial 22991: results of a Phase III study comparing 6 months of androgen suppression and irradiation versus irradiation alone for localized T1b–cT2aN0M0 prostate cancer. J. Clin. Oncol.34(Suppl. 2S), Abstract 22 (2016).
  • James ND , SydesMR, ClarkeNWet al. Celecoxib with or without zoledronic acid for hormone-naive prostate cancer: survival results from STAMPEDE (NCT002684476). J. Clin. Oncol.34(Suppl. 2S), Abstract 162 (2016).
  • Patrick-Miller LJ , ChenYH, CarducciMAet al. Quality of life (QOL) analysis from E3805, chemohormonal androgen ablation randomized trial (CHAARTED) in prostate cancer (PrCa). J. Clin. Oncol.34(Suppl. 2S), Abstract 286 (2016).
  • Scher HI , GrafR, LouwJet al. Single CTC characterization to identify phenotypic and genomic heterogeneity as a mechanism of resistance to AR signaling directed therapies (AR Tx) in mCRPC patients. J. Clin. Oncol.34(Suppl. 2S), Abstract 163 (2016).
  • Myers CE , FeldmanR, AbbottBLet al. Frequency of BRCA mutations and co-occurring alterations in prostate cancer. J. Clin. Oncol.34(Suppl. 2S), Abstract 289 (2016).
  • Hoffman-Censits JH , GrivasP, Van Der HeijdenMSet al. IMvigor 210, a Phase II trial of atezolizumab (MPDL3280A) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC). J. Clin. Oncol.34(Suppl. 2S), Abstract 355 (2016).
  • Galsky MD , HahnNM, AlbanyCet al. Phase II trial of gemcitabine + cisplatin + ipilimumab in patients with metastatic urothelial cancer. J. Clin. Oncol.34(Suppl. 2S), Abstract 357 (2016).
  • Apolo AB , InfanteJR, HamidOet al. Safety, clinical activity, and PD-L1 expression of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic urothelial carcinoma from the JAVELIN Solid Tumor Phase Ib trial. J. Clin. Oncol.34(Suppl. 2S), Abstract 367 (2016).
  • Boyerinas B , JochemsC, FantiniMet al. Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells. Cancer Immunol. Res.3(10), 1148–1157 (2015).
  • Faltas B , BhinderB, BeltranHet al. Generating a neoantigen map of advanced urothelial carcinoma by whole exome sequencing. J. Clin. Oncol.34(Suppl. 2S), Abstract 354 (2016).
  • Weinstein JN , AkbaniR, BroomBMet al. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature507(7492), 315–322 (2014).
  • Lerner SP , KimJ, KwiatkowskiDJet al. Comprehensive characterization of 412 muscle invasive urothelial carcinomas: final analysis of The Cancer Genome Atlas (TCGA) project. J. Clin. Oncol.34(Suppl. 2S), Abstract 405 (2016).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.